Koers Foamix Pharmaceuticals Ltd. Nasdaq
Aandelen
IL0011334385
Farmaceutische producten
Omzet 2024 * | 400K 374K | Omzet 2025 * | 250K 234K | Marktkapitalisatie | 35,25 mln. 32,97 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -33 mln. -30,86 mln. | Nettowinst (verlies) 2025 * | -40 mln. -37,41 mln. | EV/omzet 2024 * | 88,1 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 141 x |
K/w-verhouding 2024 * |
-2,5
x | K/w-verhouding 2025 * |
-2,6
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 91,31% |
Recentste transcriptie over Foamix Pharmaceuticals Ltd.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
David Domzalski
CEO | Chief Executive Officer | 58 | 01-03-20 |
Tyler Zeronda
DFI | Director of Finance/CFO | 38 | - |
Iain Stuart
CTO | Chief Tech/Sci/R&D Officer | 51 | 01-03-20 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Pat LePore
BRD | Director/Board Member | 69 | 10-09-20 |
Steven Basta
BRD | Director/Board Member | 59 | 01-01-15 |
Anthony Bruno
BRD | Director/Board Member | 68 | 01-03-20 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+25,83% | 661 mld. | |
+27,00% | 566 mld. | |
-6,76% | 352 mld. | |
+20,34% | 332 mld. | |
+3,00% | 283 mld. | |
+13,09% | 231 mld. | |
+5,46% | 200 mld. | |
-9,61% | 195 mld. | |
-6,26% | 145 mld. |